WE SUPPORT HEATHCARE SMEs

from science to stock exchange

CORPORATE FINANCE & BUSINESS DEVELOPMENT

IN HEALTHCARE

2 SENIOR ASSOCIATES = 4 LOW COST OFFERS

INCLUDING 4 HIGH VALUE ADDED SERVICES
( executive corporate & business development, PE fundraising, IPO & IR , corporate PR,
healthcare intelligence database)
SUPPORTING CBO+CFO FUNCTIONS
FOR BIOTECH & PHARMA START-UP
 FROM SCIENCE TO STOCK EXCHANGE

BRING CASH + REDUCE COSTS + BUILD VALUE

for biotech / pharma / medtech / CRO / Private Equity
OUR DEDICATED SUPPORTS TO HEALTHCARE SMEs COVERING CBO & CFO FUNCTIONS

• BRING CASH : through R&D partnering + Marketing & Sales + Business Development & Licensing deals
+ through financing deals ( from seed capital to IPO, M&A & follow-on financing)

• REDUCE COSTS : reduce your payroll thanks to our low cost fees : get CBO & CFO-level supports from 2
full-time & dedicated senior associates for the full cost of a young graduate .

• BUILD VALUE : by leveraging our updated assets :

BIOTECHNEWS® = corporate & PR news services covering the life sciences market targeting our large contact
database (>81K healthcare industrial dealmakers, +3000 investment bankers, +2900 biotech VC, +6000 BA ,
family offices & investors, +3500 tech journalists)
BIOFOCUS® = +20Go data analysis & market intelligence databases focused on healthcare market
BIOPHARMACAPITAL® = fundraising & Investor Relation support for biotech & pharma SMEs
TRACK RECORD = +110 deals since 99 : BD & licensing, IPOs, Financing, M&A and +38 missions since 2006
NETWORK = +6000 investors and +81 000 dealmakers in our contact database, +58 000 through linkedin
BACKGROUND = 2 senior associates , pharma PhD+ MS, 10 years in private equity + 15 years in biotech BD
 FROM SCIENCE TO STOCK EXCHANGE

4 DEDICATED OFFERS FOR BIOTECH START-UP

Acting as outsourced integrated CBO+CFO or Executive sherpa for C-level managers
OFFER 1: FULL TIME & FULLY DEDICATED CBO+CFO : monthly fees of 24 000 € before VAT = the full cost of a
fixed term employee contract under pharma legal labor agreement with an annual gross salary of 90K€.
OFFER 2 : PART TIME & SHARED CBO+CFO : for up to 2 non-competitive clients maximum in parallel :
monthly fees of 12 000 € = the full cost of a fixed term employee contract with a 45K€ annual gross salary.
OFFER 3 : PART TIME & SHARED CBO+CFO : for up to 4 clients max in parallel : monthly fees of 8 500 €
OFFER 4: FUNDRAISER : monthly retainer of 6 000 € completed by a success fees as follows :
5% on the first tranche up to 2 millions, including a minimum of € 72,000 before tax supplemented by
4% on the tranche over 2 millions supplemented by
3% on the tranche over 3 millions supplemented by
2% on the tranche over 4 millions. «success fees is calculated after deduction of the 72 000 € retainer »
Offer 1 & 2 = without any additional fees, Tim Muller can join the executive board in order to secure the
current and next financing round.
Minimum duration : 18 months in order to be aligned with main client milestones, then renewable. Price is
higher with shorter duration.
 FROM SCIENCE TO STOCK EXCHANGE

Tim MULLER snapshot resume : Pharma PhD, MS finance, MS management

10 years as private equity investor & 15 years as business developer both in healthcare, with IPO and
M&A track record : After a first R&D experience on radiopharmaceuticals at AREVA R&D (CEA/IPSN) in 1993, Tim
worked as a R&D pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabetes mellitus & CNS.
In 99, Tim joined the private equity industry (CDC enterprises now BPI & Sofimac Partners) investing in 17 healthcare
companies (8 were acquired by industrials & 5 IPOs) from his 600 deal flow proactively sourced & screened. In 2006, Tim
founded SCIENTEX, a healthcare dedicated advisory & transition management firm focused on business & corporate
development, M&A (buy & sell side), while he was advising wealthy individuals on VIX trading & working with primary &
secondary private equity funds. Since 2008, Tim led the business development activities of several biotech & pharma as
head of M&A for Pharma Omnium, VP Bus Dev of Cytune Pharma & of Tetrahedron and head of BD for the CRO Kymos.
Tim joined CROSSJECT in 2012 during its restart in order to transform its ZENEO based medtech business model
presenting a 2M€ valuation into an Euronext listed specialty pharma (IPO in feb 14 valued 65M€). After the successful
completion of a 472M$ ww R&D partnering deal on ZENEO epinephrin; Tim, acting as CBO & member of the executive
board, led & drove the $6M refinancing closed in june 2013 while managing M&A opportunities. Tim initiated & engaged
the IPO process, successfully oversubscribed 4,4 x in feb 2014 & negotiated 2 out-licensing deals for ZENEO MTX covering
China valuated 360M€ including 25% royalties & covering Indian regions including royalties between 20% to 40%. For
CROSSJECT, Tim was fully dedicated, full time, home based & commuting with 40% of ww travel and negotiated 8 term
sheets. During 2016, Tim performed +300 commercial meetings on a ww basis and met 250 investors. Complementary,
thanks to its broad healthcare database, SCIENTEX was also mandated to screen the 907 injectable drugs in order to
double CROSSJECT’s R&D portfolio : 200 injectables were ZENEO compatibles and 5 products have been selected and
highlighted by SCIENTEX supporting the 6,7M euros grant from BPI/PIAVE. During his tenure, CROSSJECT’ share rose from
€1 to €12,67. Globally, Tim has been involved in +110 corporate & business transactions, on sell & buy side, including 5
IPOs, 10 M&A, 13 out-licensing deals, 35 commercial deals, 51 financing deals with a worldwide coverage. Tim was board
member for 26 companies since 1999.
 COST COMPETITIVITY of SCIENTEX fees versus FTE
What is the real full cost of an employee **?
Make your own calculations by changing numbers in blue cases. ** validated with leading Contract Sales Organizations
What is the full cost of your employee ? COST OF CAR SERVICE: 300 euros per month (LLD)
MOBILE COST with ww mobile internet : 40 euros / month
Salary taxes in the French system (in % of the gross annual salary) RESTAURANT TICKETS : 5 euros per business days
MOBILE PC & SOFTWARE : 500+500 euros per year
LEGAL RISK ALLOWANCE FOR FIXED-TERM CONTRACT 10%
HEALTH & RETIREMENT INSURANCE : 2000+800 €/year
ANNUAL PAID LEAVE & PUBLIC HOLIDAYS & SICK LEAVE WORK21,6%
LEGAL SALARY TAXES ON GROSS SALARY : 48%-62% 48% BASED ON 9 W EEKS (45 days) OF HOLIDAYS PER YEAR + 17
DAYS OF SICK LEAVE W ORK AVERAGE IN FR = 250 OPEN
SOFT CHARGES (Car, mobile & PC, restaurant tickets) in € 9160 BUSINESS DAYS
1 m2 = 15 euros per month
DESK RENT for 15m2 2700
RECRUITMENT COST 15% 15% with human ressources in house, 25 % with
recruitment agency and up to 35% with head hunters
LEGAL 13th month's salary (pharma working agreement) 8,3%
IMPUT YOUR GROSS SALARY BUDGET HERE in blue case in euros : 45 000
FULL ANNUAL SALARY COST ALL CHARGES & TAXES INCLUDED 112 705
As a conclusion, for a company, the full annual cost of an employee with an annual gross salary of 45 000 euros
is in fact, including all taxes and charges , paid leave, risk allowance and recruitment costs closed to €112 705
GROSS ANNUAL SALARY FULL COST FACTOR
60 000 146 000 2,43 example : 45 000 euros is the
average gross annual salary of a
80 000 190 000 2,38
young graduate first job engineer
100 000 235 000 2,35

A typical day of a manager in Paris SCIENTEX : a typical home office day

From wake up to office From wake up to office: 1h, school is 5 minutes by walk
7h00-9h30 A working day
a working day 8h20-19h00
9h30-12h30 + 14h00-18h30 lunch
lunch 30 minutes
12h30-14h00 Office = home and children come back to school in 5 minutes
Back to home+ children 0h
18h30-19h30 1 coffee break in a day = 10 minutes
2 coffee breaks in a day = 15 minutes closed & holidays : 18 days per year so 243 days worked
closed & holidays : 45 days per year so 211 days worked total of hours effectively worked = 2430h/year
total of hours effectively worked = 1529h/year so SCIENTEX is + 59%
 4 SERVICES COVERING CORPORATE AFFAIRS :
private equity financing, IPO & follow-on, M&A, IR, BusDev & Licensing, R&D partnering

1. SCIENTEX : consultancy & transition and executive management firm, focused on corporate
finance and business development in healthcare; holding of billing, thus avoiding high costs,
heaviness, sick leaves, holidays and constraints of the french pharma labor agreement
2. BIOPHARMAcapital : contact database with + 6000 contacts inside public & private equity,
familly office and business angels, +2900 biotech VC ww.
3. BIOfocus : healthcare database (+20Go), built & updated from main leading market
intelligence providers and investment banks.
4. BIOTECHnews : corporate and PR news push services dedicated to the life sciences market
and targeting +80 000 healthcare dealmakers (pharmaceutical, biotech, investment banks)
 Supporting CBO & CFO functions for biotech & pharma
Leverage the track record of the 2 associates :
Working with the 2 SCIENTEX'associates will cost you the same full cost of a young graduate
fixed term contract (average gross salary 45K€/y FTE) so around 12K€/month VAT excluded on a
full time basis, for 1 full time associate : 1 associate focused in front office commuting and facing
clients & investors while the second associate is supporting in back office
TRACK RECORD of Scientex’s associates since 1999 :

+110 deals = sell & buy side, including 5 IPOs (4 as investor, 1 as executive board member),
10 M&A, 13 out-licensing, 35 commercial , 51 financing
+32 missions during the last 10 years generating +2,5M€ of net fees for SCIENTEX.
26 board member position since 1999
+600 BP sourced & screened as VC & venture partner, 17 private equity investments in life
sciences
Huge network : +6000 investors (public & private & family offices), +1200 wealthy
individuals & +80 000 biopharma dealmakers, 2900 biotech VC ww, +3500 tech journalists,
+58 000 followers & contacts through linkedin
Healthcare database >20Go, built from leading market intelligence providers & investment
banks
Background of the 2 associates : MBA & pharma PhD background with +20 years inside
European private equity funds, biotech and mid-size pharmaceutical industry.
SCIENTEX CLIENTS SINCE 2006 : +38 missions
 CROSSJECT case study : 19 months to transfom a private
start-up medtech into an Euronext listed specialty pharma
The 2 associates of SCIENTEX recently realized a dual track mission for Crossject, strongly
supporting its tech founding CEO by covering CFO&CBO functions from 2012 to 2018.

SCIENTEX joined CROSSJECT mid 2012 (9 FTE) during its restart in order to transform its device
based private start-up medtech business model presenting a 2M€ valuation into an Euronext
listed specialty pharma (IPO in feb 14 valued €65M & €17M raised). After the successful
completion of a 472M$ ww out-licensing deal on ZENEO epinephrine in Q1-2013; Tim, as Chief
Business Officer & member of the executive board, led & drove the €5M refinancing closed in
may 2013 while managing M&A opportunities. Tim initiated & engaged the IPO process,
successfully oversubscribed 4,4 x in feb 2014 & negotiated 2 out-licensing deals for ZENEO MTX
covering China valuated 360M€ including 25% royalties & covering Indian regions including
royalties between 20% to 40%. For CROSSJECT, during 6 years, 70 FTE in 2018, Tim was fully
dedicated and full time, home based & commuting with 40% of ww travel while driving business
development & licensing (+1000 face to face meetings in 6 years, 8 term sheets sourced,
negotiated, signed & several deals fully negotiated). During 2016, Tim performed around 300
commercial meetings on a ww basis and met 250 investors. Complementary, thanks to its broad
healthcare database, SCIENTEX has also been mandated to screen the 907 injectable drugs in
order to double CROSSJECT’s R&D portfolio : 200 injectables were ZENEO compatibles and 5
products have been selected after beeing strongly recommended and highlighted by SCIENTEX
supporting the €6,7M grant from BPI/PIAVE. During his tenure, CROSSJECT’ share rose from €1
to €12,67.
 CROSSJECT case study : How we revived its business
development activities ?
In term of BD&L activities, we are almost 3 times more productive in meeting with
industrials & investors
● ranked 1st at BIO USA june 2016 by the organizers thanks to +77 scheduled meetings
where only 15% of the 6322 other partnering delegates reached to have +25 meetings,
● ranked 5th at BIOEUROPE 2016 with 50 1to1 meetings in 2,5 days, while the 3647
delegates reached to have an average of 12 meetings/delegates
 AWARDS
Since 2016, SCIENTEX received 14 business & corporate awards :

1. APRIL 2016 : Most Efficient Healthcare start-up business boutique in Europe, by ACQUISITION
INTERNATIONAL, the voice of corporate finance
2. OCTOBER 2016 for its excellence in corporate affairs support - France, by WEALTH& FINANCE
international
3. JANUARY 2017 : European Life Sciences Business Boutique of the Year in Corporate LiveWire’s 2017
Innovation & Excellence Awards.
4. FEBRUARY 2017 : Most engaged & results driven Contract Business Development Organization in
Europe by ACQUISITION INTERNATIONAL
5. MARCH 2017 for its excellence in international business management, by WEALTH& FINANCE
international
6. MARCH 2018 : Best business development company in Europe, by ACQUISITION INTERNATIONAL, the
voice of corporate finance
7. JUNE 2018: Efficient healthcare start-up business boutique of the year 2018 - FRANCE, by GLOBAL
BUSINESS INSIGHT
8. APRIL 2019 : Most Efficient Healthcare start-up business boutique in Europe, by GLOBAL VENTURE
AWARDS
9. September 2019 : European Business Development Boutique of the year in Healthcare, by ACQ5
Global awards
10. September 2019 : European Healthcare Business development professional of the year, by Global
Corporate Livewire awards 2019
11,12, 13 & 14. May 2020, 21 ,22 and 23 : Business development professional of the year in Healthcare-
EUROPE, by ACQ5 Global awards and Gamechangers Global Awards
 TOP 10 REASONS to use Scientex associate's

1. TRACK RECORD : +38 missions since 2006 & +110 various business & financing deals since
1998 on both sell & buy sides from seed capital to public offerings, including 17 start-up
financed as ex biotech VC (600 business plan screened) and M&A and BusDev & licensing &
R&D partnering
2. BIOPHARMA BUSINESS RECOGNITION : 14 Business awards received to date, including
"Best Business Development Company in Europe" in 2018, 19, 20, 21, 22 and 2023 : see
http://www.scientex.eu/awards/
3. MISSION FOCUS : Biotech & pharma only focused on business development & financing
activities = private equity financing, IPO & follow-on, M&A, IR, BusDev & Licensing, R&D
partnering
4. LOW COST FEES : Working with the 2 SCIENTEX'associate will cost you the same full cost of a
young graduate fixed term contract (average gross salary 45K€/y FTE) so around
12K€/month VAT excluded on a full time basis per associates : 1 in front office facing clients
and 1 in back office in order to keep momentum.
5. VERY STRONG SUPPORT = 2430 HOURS WORKED per year : SCIENTEX's support is +59%
compared with the 1529h/year of a full time employee under the french pharmaceutical
legal labor agreement. As an example, we reached our maximum capacity in 2016 with 300
business meeting with pharma industrials & 250 investors met on a ww basis.
 TOP 10 REASONS to use Scientex associate's

6. HUGE NETWORK : +6000 investors & +80 000 biopharma dealmakers on a ww basis in our
contact database, +3500 tech journalists, +56 000 followers & contacts through linkedin,
audience reachable > 4 millions through 100 linkedin healthcare & investors groups
memberships.
7. HEALTHCARE DATABASE INCLUDED : +20 Go data analysis & market intelligence database
focused on healthcare markets including all pipeline/product forecast/epidemiology/KOL
insights/ competition analysis... on any therapeutic areas. Our database is built &
downloaded from leading market intelligence providers & investment banks.
8. DEDICATED & FULL TIME : SCIENTEX' associates are working exclusively, dedicatedly & on a
full time basis for one single client only with a worldwide coverage without any outsourcing
to juniors.
9. 20 years BACKGROUND : SCIENTEX'associates have both Master specialized & pharma PhD
background with a career inside european private equity funds, biotech and mid-size
pharmaceutical industry, with financing, IPO and deal track record,
10. FLEXIBLE & INTENSIVE SUPPORT : Working with SCIENTEX'associates is the best way to
remove huge costs & constraints & sick leaves & holidays of french labor legal agreement :
only one week of holidays per year (in winter) and less than 15 sick days in 20 years.